Exchange: NYSE·Updated 09:37 AM EDT

NVS News

News
all
press releases
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.read more...
Benzinga
More News
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen's Phase III trial missed its endpoint; other biotech stocks also declined.read more...
Benzinga
Novartis twin drug setbacks pile pressure on pipeline and CEO
Novartis twin drug setbacks pile pressure on pipeline and CEO...
Yahoo! Finance: News
Attacks Halt Saudi Energy Sites, Novartis Drops Most in 6 Years The Opening Trade 9/8/2026
Attacks Halt Saudi Energy Sites, Novartis Drops Most in 6 Years | The Opening Trade 9/8/2026...
Bloomberg Markets and Finance-YouTube
Pharma major plummets over 10% after third trial disappointment in a week
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors...
CNBC: Healthcare
United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday
Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey's earnings expected.read more...
Benzinga
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down
Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.
Zacks
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.
Zacks
Futures Drop As Iran Hostilities Send Brent To 6 Week High Above $97
Futures Drop As Iran Hostilities Send Brent To 6 Week High Above $97 US stock futures slipped in cautious, low volume trading as the latest Middle East escalation pushed oil prices higher, lifting bond yields in Europe and Asia. As of 9:00am ET, S&P futures were down 0.2% with Nasdaq...
Zero Hedge
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah
AZN's Etcamah wins accelerated FDA approval for certain advanced breast cancer patients, backed by a 56% risk reduction in progression or death.
Zacks

Advertisement|Remove ads.